logo
ScreenersREIT EarningsREIT SectorsIndustries
Logo

PepGen Inc.

PEPG

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugatedā€¦ read more

Healthcare

Biotechnology

4 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$3.05

Price

+4.81%

$0.14

$2.91

Previous Close

$2.98

Open

Premium

52w Discount
Market Cap

$210.966m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$77.216m

+13.9%

1y CAGR

-0.1%

3y CAGR

-3.5%

5y CAGR
EPS

-$2.10

+0.9%

1y CAGR

+13.4%

3y CAGR

+16.4%

5y CAGR
Book Value

$133.980m

$156.295m

Assets

$22.315m

Liabilities

$16.561m

Debt
Debt to Assets

10.6%

-0.2x

Debt to EBITDA
Free Cash Flow

-$77.270m

+5.7%

1y CAGR

-3.0%

3y CAGR

-5.6%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.